Skip to main navigation
Quantum Si
  • Technology
  • Products
  • Applications
    • Protein Identification
    • PTM Analysis
  • Resources
  • Investors
    • News
    • Events and Presentations
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • About Us
    • Careers
    • Leadership
  • Contact Us
Select Page
h
    • Technology
    • Products
    • Applications
      • Protein Identification
      • PTM Analysis
    • Resources
    • Investors
      • News
      • Events and Presentations
      • Stock Information
      • Financials
      • Governance
      • Investor Resources
    • About Us
      • Careers
      • Leadership
    • Contact Us

News Details

  • Overview
  • News
  • Events & Presentations
    Events Presentations
  • Stock Information
    Stock Quote & Chart Analyst Coverage Historic Price Lookup
  • Financials
    Quarterly Results Annual Reports SEC Filings
  • Governance
    Governance Highlights Leadership Board of Directors Committee Composition
  • Investor Resources
    Investor FAQs Investor Email Alerts Investor Contact

Quantum-Si to Present at the 2022 Jefferies Healthcare Conference

May 25, 2022
PDF Version

GUILFORD, Conn.--(BUSINESS WIRE)-- May 25, 2022--Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing single molecule protein sequencing, today announced that it will be participating in the 2022 Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY, on June 8-10, 2022.

Quantum-Si’s management is scheduled to present on Friday, June 10, 2022 at 8:30 am ET.

A live and archived webcast of the event will be available in the Investors section of the Quantum-Si website under Events & Presentations.

About Quantum-Si Incorporated

Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005116/en/

Investors
Juan Avendano
Mike Cavanaugh
ir@quantum-si.com

Media
Karen Chase
QSI-PR@westwicke.com

Source: Quantum-Si Incorporated
  • Print Page
  • Email Alerts
  • RSS Feeds
  • Contact IR
h
© Copyright 2023 QuantumSi | All rights reserved.
Follow us
  • Facebook
  • Twitter
  • LinkedIn
  • Instagram
  • Youtube